Company intelligence / Profile preview

RONAholdings

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

RN0191 (PCSK9 siRNA) completed Phase 1 in Australia and China, advancing to Phase 2. RN0361 (APOC3 siRNA) completed FIH Phase 1 in Australia and received FDA IND for Phase 2. Multiple preclinical/IND-stage programs in obesity, NASH, hypertension, and CNS diseases.

Therapeutic areas: NephrologyEndocrinologyCardiovascularNeurologyGastroenterologyMetabolic Disorders
Modalities: siRNA
Industry: Biotech

Partnerships

EnnovaBio (co-development for liver diseases)Keymed (co-development for Glomerulonephritis)

Beyond the preview

Go deeper on RONAholdings.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RONAholdings.

Explore the full profile